BridgeBio Pharma (NASDAQ:BBIO) CAO Maricel Apuli Sells 510 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 510 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the completion of the sale, the chief accounting officer owned 123,945 shares of the company’s stock, valued at approximately $9,210,352.95. This trade represents a 0.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Maricel Apuli also recently made the following trade(s):

• On Monday, December 8th, Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $74.26, for a total value of $148,520.00.

BridgeBio Pharma Trading Down 2.5%

NASDAQ:BBIO traded down $1.92 during trading hours on Wednesday, hitting $73.93. The stock had a trading volume of 2,365,520 shares, compared to its average volume of 3,243,876. The company has a market cap of $14.25 billion, a PE ratio of -17.69 and a beta of 1.13. The business has a 50 day simple moving average of $75.70 and a two-hundred day simple moving average of $63.72. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94.

Institutional Trading of BridgeBio Pharma

Hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp acquired a new position in shares of BridgeBio Pharma during the first quarter valued at $35,000. Vanguard Personalized Indexing Management LLC lifted its holdings in BridgeBio Pharma by 5.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 16,178 shares of the company’s stock worth $699,000 after purchasing an additional 772 shares during the period. CWM LLC grew its position in BridgeBio Pharma by 29.8% in the 2nd quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after buying an additional 1,569 shares in the last quarter. Allianz Asset Management GmbH grew its position in BridgeBio Pharma by 57.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 12,300 shares of the company’s stock valued at $531,000 after buying an additional 4,500 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in BridgeBio Pharma during the 2nd quarter valued at about $229,000. Institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BBIO. HC Wainwright raised their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Partners raised their price target on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Raymond James Financial set a $89.00 price target on shares of BridgeBio Pharma and gave the company an “outperform” rating in a report on Thursday, February 12th. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a research note on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective on the stock. Finally, TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $82.05.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.